東富龍(300171.SZ):公司主營產品的技術、性能已達到國際先進水平
格隆匯5月8日丨東富龍(300171.SZ)在投資者互動平台表示,公司深耕生物醫藥行業三十餘載,圍繞“M+E+C”的業務發展模式(其中“M”即“Machinery”——設備,“E”即“Engineering”——工程,“C”即“Consumable”——耗材)佈局產業上下游,能夠為客户提供設備+耗材+工程一體化的智能解決方案,提供量身定製的一站式服務。公司主營產品的技術、性能已達到國際先進水平,較進口設備具有成本優勢,可以幫助製藥企業有效降低生產成本,提高市場競爭力。同時,公司靈活的生產服務模式能更好的服務於本土客户的需求,提供更貼合實際的定製化服務,滿足不同客户的個性化需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.